What is CORT's current stock price?

As of now, CORT is trading at $34.73, with a daily change of -1.86%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

CORT Stock Analysis & IQ Rating | Corcept Therapeutics

CORT

Corcept Therapeutics

$34.73

-$0.66 | -1.86%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$117.33

MKT CAP

$3.65B

52W Low

$32.99

VOL

$995.00K

P/E Ratio

39.21

AVG VOL

$2.26M

RSI

21.81

TREND

Downtrend

CORT Stock IQ

Login to see Corcept Therapeutics (CORT) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

CORT Target Price

Login to display

Strengths

CORT Rewards

Upgraded on attractively valued

CORT Rewards

Earnings are forecast to grow

CORT Price Performance

$83.76 (-58.54%)

$72.98 (-52.41%)

$69.57 (-50.08%)

$66.91 (-48.09%)

1year

6month

3month

1month

CORT Analysts Opinion

CORT overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

CORT Analysts Opinion

CORT Analysts opinion is negative but has improved from the past 3 months

CORT Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

17%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

0%

CORT Street Sentiment

CORT Street Sentiment is unimpressive and have negative views on the near-term outlook

CORT Risk Level

CORT has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

CORT Performance Sentiment

Sentiments overview associated with CORT events and the stock performance.

17%

75%

Positive

Negative

2 out of 12
events present

9 out of 12
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$34.73

Resistance
Price

$34.73

Current Price Range

$86.11

Show methods +

Recently Viewed

Close Price

Change

CORT

Corcept Therapeutics

34.73

-1.86%

BCAX

Bicara Therapeutics Inc.

16.75

+0.36%

SATL

Satellogic

3.56

+2.01%

EL

Estee Lauder

115.05

-0.52%

CORT Latest Analysis +

INVESTOR ALERT: Investigation of Corcept Therapeutics Incorporated (CORT) by Holzer & Holzer LLC. ) complied with federal securities laws. On December 31 2025 Corcept disclosed that the United States Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism. Following this news the price of the Company'.s stock dropped.

Wed Jan 14, 2026

$37.04 | +1.90%

Activity

Price Targets Lowered on Corcept Therapeutics (CORT) After FDA Letter. Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On January 2 Canaccord Genuity cut its price target on Corcept Therapeutics Incorporated (NASDAQ:CORT) from $140 to $99 but kept its Buy rating on the stock. This adjustment comes after the company reported that the FDA [….]

Fri Jan 9, 2026

$37.50 | +2.66%

Potential

Rating

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant Shares Tank 50% - Hagens Berman. SAN FRANCISCO Jan. 6 2026 /PRNewswire/ -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31 2025 after the company announced its receipt of a complete response letter (CRL) from the FDA for its proposed treatment of...

Tue Jan 6, 2026

$35.73 | +2.23%

Momentum

Corcept Therapeutics stock price target lowered to $90 at H.C. Wainwright.

Fri Jan 2, 2026

$38.20 | +9.77%

Potential

Why Corcept Therapeutics Plummeted by 50% Today. Key PointsThe FDA declined to approve its relacorilant.

Wed Dec 31, 2025

$34.80 | -50.42%

Momentum

Corcept Stock Plunges 50% After FDA Rejects Relacorilant Application . (RTTNews) - Corcept Therapeutics Incorporated (CORT) shares fell 50.50% trading at $34.74 down $35.45 after the company announced it received a Complete Response Letter (CRL) from the United States Food and Drug Administration regarding its relacorilant application.

Wed Dec 31, 2025

$34.80 | -50.42%

Activity

Corcept Receives FDA Complete Response Letter For Relacorilant Stock Down . (RTTNews) - Corcept Therapeutics (CORT) on Wednesday said the United States Food and Drug Administration has issued a Complete Response Letter for the New Drug Application of relacorilant to treat hypertension secondary to hypercortisolism.

Wed Dec 31, 2025

$34.80 | -50.42%

Activity

Momentum

Corcept Therapeutics Stock Sinks On FDA Setback For Relacorilant. CORT) stock tumbled Wednesday after the .The commercial-stage company is engaged in the discovery and development of medications to treat severe endocrinologic oncologic metabolic and neurologic disorders by modulating the effects of the hormone cortisol.The United States Food and Drug Administration (FDA) on Wednesday issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant for hypertensio

Wed Dec 31, 2025

$34.80 | -50.42%

Momentum

Corcept Therapeutics (CORT) Shares Cross Below 200 DMA. In trading on Tuesday shares of Corcept Therapeutics Inc (Symbol: CORT) crossed below their 200 day moving average of $73.97 changing hands as low as $69.91 per share. Corcept Therapeutics Inc shares are currently trading off about 12.1% on the day. The chart below shows the

Tue Dec 30, 2025

$70.19 | -12.06%

Technical

Major Exercise Alert: Joseph K Belanoff Exercises Options Worth $41.51M At Corcept Therapeutics. A large exercise of company stock options by CORT) was disclosed in a new SEC filing on December 29 as part of an insider exercise.United States Securities and Exchange Commission revealed that Belanoff Chief Executive Officer at Corcept Therapeutics exercised stock options for 550000 shares of CORT resulting in a transaction value of $41508500.As of Tuesday morning Corcept Therapeutics Inc is a comm

Tue Dec 30, 2025

$70.19 | -12.06%

Activity

FAQ About CORT Stock Insights

What is CORT current stock price?

What are CORT stock strengths?

What is CORT Risk Level?

What is CORT market cap and volume?

What is CORT current Stock IQ?

Should I buy CORT stock right now?

Is CORT a Strong Buy right now?

What does a 'Strong Buy' rating mean for CORT?

What does a 'Strong Sell' rating mean for CORT?

What factors influence CORT's Stock IQ?

Explore our CORT Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored CORT Stock Strategies
Effective Risk Management

FIND US ON

Receive our CORT Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

CORT

Corcept Therapeutics

Set Alerts

Current Price

$34.73

-$0.66 | -1.86%

52W High

$117.33

MKT CAP

$3.65B

52W Low

$32.99

VOL

$995.00K

P/E Ratio

39.21

AVG VOL

$2.26M

RSI

21.81

TREND

Downtrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Stock Insights

Strengths

CORT Rewards

Upgraded on attractively valued

CORT Rewards

Earnings are forecast to grow

CORT Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

17%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

0%

CORT Street Sentiment

CORT Street Sentiment is unimpressive and have negative views on the near-term outlook

CORT Risk Level

CORT has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

CORT Performance Sentiment

Sentiments overview associated with CORT events and the stock performance.

17%

75%

Positive

Negative

2 out of 12
events present

9 out of 12
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$34.73

Resistance
Price

$34.73

Current Price Range

$86.11

Show methods +

Latest Analysts Recommendations

Date

Action

Rating

Firm

Dec 17, 2025

Initiate

Neutral

UBS

Nov 25, 2025

Reiterate

Buy

H.C. Wainwright

Oct 20, 2025

Reiterate

Buy

HC Wainwright & Co.

Oct 10, 2025

Reiterate

Buy

HC Wainwright & Co.

Sep 26, 2025

Reiterate

Buy

Canaccord Genuity

CORT Stock IQ

Login to unlock Corcept Therapeutics (CORT) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

CORT Latest Analysis

INVESTOR ALERT: Investigation of Corcept Therapeutics Incorporated (CORT) by Holzer & Holzer LLC. ) complied with federal securities laws. On December 31 2025 Corcept disclosed that the United States Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism. Following this news the price of the Company'.s stock dropped.

Wed Jan 14, 2026

$37.04 | +1.90%

Activity

Price Targets Lowered on Corcept Therapeutics (CORT) After FDA Letter. Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On January 2 Canaccord Genuity cut its price target on Corcept Therapeutics Incorporated (NASDAQ:CORT) from $140 to $99 but kept its Buy rating on the stock. This adjustment comes after the company reported that the FDA [….]

Fri Jan 9, 2026

$37.50 | +2.66%

Potential

Rating

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant Shares Tank 50% - Hagens Berman. SAN FRANCISCO Jan. 6 2026 /PRNewswire/ -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31 2025 after the company announced its receipt of a complete response letter (CRL) from the FDA for its proposed treatment of...

Tue Jan 6, 2026

$35.73 | +2.23%

Momentum

Corcept Therapeutics stock price target lowered to $90 at H.C. Wainwright.

Fri Jan 2, 2026

$38.20 | +9.77%

Potential

Why Corcept Therapeutics Plummeted by 50% Today. Key PointsThe FDA declined to approve its relacorilant.

Wed Dec 31, 2025

$34.80 | -50.42%

Momentum

Corcept Stock Plunges 50% After FDA Rejects Relacorilant Application . (RTTNews) - Corcept Therapeutics Incorporated (CORT) shares fell 50.50% trading at $34.74 down $35.45 after the company announced it received a Complete Response Letter (CRL) from the United States Food and Drug Administration regarding its relacorilant application.

Wed Dec 31, 2025

$34.80 | -50.42%

Activity

Corcept Receives FDA Complete Response Letter For Relacorilant Stock Down . (RTTNews) - Corcept Therapeutics (CORT) on Wednesday said the United States Food and Drug Administration has issued a Complete Response Letter for the New Drug Application of relacorilant to treat hypertension secondary to hypercortisolism.

Wed Dec 31, 2025

$34.80 | -50.42%

Activity

Momentum

Corcept Therapeutics Stock Sinks On FDA Setback For Relacorilant. CORT) stock tumbled Wednesday after the .The commercial-stage company is engaged in the discovery and development of medications to treat severe endocrinologic oncologic metabolic and neurologic disorders by modulating the effects of the hormone cortisol.The United States Food and Drug Administration (FDA) on Wednesday issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant for hypertensio

Wed Dec 31, 2025

$34.80 | -50.42%

Momentum

Corcept Therapeutics (CORT) Shares Cross Below 200 DMA. In trading on Tuesday shares of Corcept Therapeutics Inc (Symbol: CORT) crossed below their 200 day moving average of $73.97 changing hands as low as $69.91 per share. Corcept Therapeutics Inc shares are currently trading off about 12.1% on the day. The chart below shows the

Tue Dec 30, 2025

$70.19 | -12.06%

Technical

Major Exercise Alert: Joseph K Belanoff Exercises Options Worth $41.51M At Corcept Therapeutics. A large exercise of company stock options by CORT) was disclosed in a new SEC filing on December 29 as part of an insider exercise.United States Securities and Exchange Commission revealed that Belanoff Chief Executive Officer at Corcept Therapeutics exercised stock options for 550000 shares of CORT resulting in a transaction value of $41508500.As of Tuesday morning Corcept Therapeutics Inc is a comm

Tue Dec 30, 2025

$70.19 | -12.06%

Activity

Discover CORT Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of CORT. We're here to help you make informed investment decisions today.

FIND US ON

Receive our CORT Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

CORT Stock trends

CORT Stock performance

CORT Stock analysis

CORT investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

CORT Stock Analysis & IQ Rating | Corcept Therapeutics

CORT Stock IQ

CORT Target Price

CORT Analysts Opinion

CORT Street Sentiment

CORT Risk Level

CORT Performance Sentiment

Technical Price Levels

Explore our CORT Stock insights

Receive our CORT Daily Alerts

CORT Street Sentiment

CORT Risk Level

Technical Price Levels

Latest Analysts Recommendations

Discover CORT Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of CORT. We're here to help you make informed investment decisions today.

Receive our CORT Daily Alerts

CORT Alerts